Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL).

被引：8
|
作者：
Khushalani, Nikhil I.
Kim, Youngchul
Gibney, Geoffrey Thomas
Kudchadkar, Ragini Reiney
Eroglu, Zeynep
Markowitz, Joseph
Czupryn, Maria P.
Thebeau, Melissa S.
McCormick, Lori
Richards, Allison
Weber, Jeffrey S.
机构：
[1] H Lee Moffitt Canc & Ctr Res Inst, Tampa, FL USA
[2] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] NYU Langone Med Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9586
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma
    Sullivan, Ryan Joseph
    LANCET, 2020, 395 (10236): : 1524 - 1525
  • [2] Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma
    Freeman, Morganna Louise
    Shoushtari, Alexander Noor
    Betts, Keith A.
    Gupte-Singh, Komal
    Du, Ella X.
    Ritchings, Corey
    Rao, Sumati
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
    Ascierto, P. A.
    Del Vecchio, M.
    Merelli, B.
    Gogas, H.
    Arance Fernandez, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J. J.
    Chiarion Sileni, V.
    Marquez-Rodas, I.
    Butler, M. O.
    Di Giacomo, A. M.
    Pe Benito, M.
    Soomro, R.
    Askelson, M.
    Weber, J. S.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S656 - S656
  • [4] Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
    Khushalani, Nikhil, I
    Vassallo, Melinda
    Goldberg, Judith D.
    Eroglu, Zeynep
    Kim, Younchul
    Cao, Biwei
    Ferguson, Robert
    Monson, Kelsey R.
    Kirchhoff, Tomas
    Amato, Carol M.
    Burke, Paulo
    Strange, Ann
    Monk, Emily
    Gibney, Geoffrey Thomas
    Kudchadkar, Ragini
    Markowitz, Joseph
    Brohl, Andrew S.
    Pavlick, Anna
    Richards, Alison
    Woods, David M.
    Weber, Jeffrey
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (11)
  • [5] Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915).
    Long, Georgina V.
    Schadendorf, Dirk
    Del Vecchio, Michele
    Larkin, James
    Atkinson, Victoria
    Schenker, Michael
    Pigozzo, Jacopo
    Gogas, Helen J.
    Dalle, Stephane
    Meyer, Nicolas
    Ascierto, Paolo A.
    Sandhu, Shahneen
    Eigentler, Thomas
    Gutzmer, Ralf
    Hassel, Jessica C.
    Robert, Caroline
    Carlino, Matteo
    Di Giacomo, Anna Maria
    Butler, Marcus O.
    Munoz-Couselo, Eva
    Brown, Michael P.
    Rutkowski, Piotr
    Haydon, Andrew
    Grob, Jean-Jacques
    Schachter, Jacob
    Queirolo, Paola
    Menzies, Alexander
    Re, Sandra
    Bas, Tuba O.
    de Pril, Veerle
    Tenney, Daniel
    Tang, Hao
    Weber, Jeffrey S.
    CANCER RESEARCH, 2021, 81 (13)
  • [6] SAFETY PROFILE OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) COMBINATION THERAPY IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Sznol, Mario
    Ferrucci, Pier
    Hogg, David
    Atkins, Michael
    Wolter, Pascal
    Guidoboni, Massimo
    Lebbe, Celeste
    Kirkwood, John
    Schachter, Jacob
    Daniels, Gregory
    Hassel, Jessica
    Cebon, Jonathan
    Gerritsen, Winald
    Atkinson, Victoria
    Thomas, Luc
    Mccaffrey, John
    Power, Derek
    Jiang, Joel
    Hodi, Stephen
    Wolchok, Jedd
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 118 - 118
  • [7] PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
    Long, G. V.
    Larkin, J.
    Ascierto, P. A.
    Hodi, F. S.
    Rutkowski, P.
    Sileni, V.
    Hassel, J.
    Lebbe, C.
    Pavlick, A. C.
    Wagstaff, J.
    Schadendorf, D.
    Dummer, R.
    Hogg, D.
    Haanen, J. B. A. G.
    Corrie, P.
    Hoeller, C.
    Horak, C.
    Wolchok, J.
    Robert, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] PD-L1 EXPRESSION AS A BIOMARKER FOR NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) AND NIVO ALONE IN ADVANCED MELANOMA (MEL): A POOLED ANALYSIS
    Long, Georgina
    Larkin, James
    Ascierto, Paolo
    Hodi, Stephen
    Rutkowski, Piotr
    Chiarion-Selini, Vanna
    Hassel, Jessica
    Lebbe, Celeste
    Pavlick, Anna
    Wagstaff, John
    Schadendorf, Dirk
    Dummer, Reinhard
    Hogg, David
    Haanen, John
    Corrie, Pippa
    Hoeller, Christopher
    Horak, Christine
    Wolchok, Jedd
    Robert, Caroline
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 126 - 126
  • [9] Characterisation of Complete Responses (CRS) in Patients With Advanced Melanoma (MEL) who Received the Combination of Nivolumab (NIVO) and Ipilimumab (IPI), NIVO, or IPI Alone
    Robert, Caroline
    Larkin, James
    Ascierto, Paolo A.
    Long, Georgina V.
    Hassel, Jessica C.
    Schadendorf, Dirk
    Hodi, F. Stephen
    Lebbe, Celeste
    Grob, Jean-Jacques
    Grossmann, Kenneth
    Wagstaff, John
    Chesney, Jason
    Hogg, David
    Bechter, Oliver
    Marquez-Rodas, Ivan
    Pavlick, Anna C.
    DanaWalker
    Bhore, Rafia
    Postow, Michael A.
    Wolchok, Jedd D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 136 - 137
  • [10] Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
    Robert, C.
    Larkin, J.
    Ascierto, P. A.
    Long, G. V.
    Hassel, J. C.
    Schadendorf, D.
    Hodi, F. S.
    Lebbe, C.
    Grob, J-J.
    Grossmann, K.
    Wagstaff, J.
    Chesney, J.
    Hogg, D.
    Bechter, O.
    Marquez-Rodas, I.
    Pavlick, A. C.
    Walker, D.
    Bhore, R.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2017, 28
12345